NCT07796295Not yet recruiting
Prescribing the Right Agent for Depression in Adults
Prescribing the Right Agent for Depression in Adults (PRADA): a Double-blind, Randomised Controlled Trial Using a Web-based Multi-modal Clinical Decision Support System and Genetic Information to Personalise Antidepressant Treatment in Diverse Clinical Settings Across the Globe
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Depression is a common mental health problem affecting almost 300 million people worldwide. Antidepressants are recommended as one of the first line treatments for people with moderate-to-severe symptoms of depression. In our recent trial, PETRUSHKA, on the acute treatment of depression, we demonstrated that the PETRUSHKA Tool, an evidence-based shared decision support system to personalise antidepressant treatment, in comparison with usual care reduced by almost 40% the number of participants stopping their antidepressant early, also improving their depression and anxiety symptoms. To identify the best treatment for each individual, the PETRUSHKA Tool used clinical and demographic predictors. Pilot data show that genetic information can aid stratification of people experiencing depression and better target their treatment. Genetic data can be collected using low-cost DNA-sequencing technology in diverse clinical settings and low-resource environments. Hence, we hypothesised that individual-level pharmacogenomic information can further personalise antidepressant treatment. In this project called PRADA ("Prescribing the Right Agent for Depression in Adults"), we will develop and test in a global trial across Ethiopia, Pakistan and the UK, an evidence-based multimodal web-tool to help participants and clinicians choose the best pharmacological treatment for depression jointly, based on participant preferences and their individual clinical, demographic, cultural, and also genetic profile (PRADA Tool). We will compare the new tool with the PETRUSHKA Tool in a blind fashion, measuring adherence to antidepressant treatment, clinical response and quality of life over a 12-month follow-up.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 2142 (estimated)
- First submitted
- 27 Aug 2026
- Start date
- 1 Oct 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Oxford
- Diseases
- Depression
- NCT number
- NCT07796295
What you commit to
- Study type: Interventional
- Planned participants: 2142
- From 1 Oct 2026 to the primary completion date, 31 Dec 2027
- 3 sites in 3 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current or historical diagnosis (lifetime) of ADHD, bipolar disorder, dementia, mania/hypomania, psychosis/schizophrenia
- Current or historical diagnosis (within 10 years) of any eating disorders, PTSD, OCD or alcohol/substance use disorder
- Known diagnosis of arrhythmias (including Q-T prolongation, heart block), recent myocardial infarction (within 5 years), difficult-to-treat epilepsy, acute porphyrias;
Other
- Taken an antidepressant in the preceding 4 weeks at a therapeutic dose;
- Treatment Resistant Depression (i.e., having tried 2 or more antidepressants for the same depressive episode at adequate dose and time);
- Requires urgent mental care or admission (including suicidal intent/plans);
- Concurrently enrolled in another investigational medicinal product (IMP) trial that, in the opinion of the investigator, is likely to interfere with the PRADA trial or an interventional trial about depression;
- Pregnant, planning pregnancy or lactating (self-reported);
- Unable to give blood sample for genetic analysis.
Who the study is looking for
- Aged 18-74 years inclusive;
- Willing and able to give informed consent for participation in the trial;
- Clinical primary diagnosis of major depressive episode, for which an antidepressant is clinically indicated;
- PHQ-9 score of at least 10;
- Willing and able to start antidepressant treatment as monotherapy;
- Able to understand and answer self-administered questionnaires in their local language.
Age in the registry: 18 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Amanuel Mental Specialized Hospital Coordinator of this site? Confirm its status | Addis Ababa | Ethiopia | Unknown status |
| NIHR Clinical Research Facility Oxford Health Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
| Pakistan Institute of Living and Learning (PILL) Coordinator of this site? Confirm its status | Karachi | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.